Compare semaglutide 2.4mg prices across every GPhC-registered UK pharmacy. All doses from 0.25mg to 7.2mg. Verified weekly. No pharmacy pays to rank first.
MHRA approvedNICE TA875NICE cardiovascular guidance — April 2026semaglutide · Novo NordiskOnce weekly injection
15–17%avg. weight loss at 68 wks
£89lowest price/month
10pharmacies tracked
GPhC-verified only No paid placements Updated April 2026
Prices by dose
Verified April 2026
Starting dose — taken for 4 weeks before increasing to 0.5mg.
Type:
Sort:
Pharmacy
Price / month
Trustpilot
Verified
Seen a cheaper price somewhere?
Spotted a lower price?
We verify all submissions and update our listings weekly. Your tip helps other patients save money.
Important: Private prescription only. Wegovy is a prescription-only medicine — a clinical assessment is required before any pharmacy can supply it. Always verify pharmacy registration at pharmacyregulation.org.
About Wegovy
How it works
Wegovy contains semaglutide, which mimics the naturally occurring hormone GLP-1 (glucagon-like peptide-1). It acts on receptors in the brain that control hunger and satiety, reducing appetite and slowing gastric emptying so food stays in the stomach longer. The result is that patients feel full more quickly and for longer, and experience fewer food cravings. It is injected once a week under the skin of the stomach, thigh, or upper arm.
Unlike Mounjaro (tirzepatide), which acts on two receptors (GLP-1 and GIP), Wegovy acts on GLP-1 alone. However, Wegovy is the only GLP-1 medication with proven cardiovascular benefit — meaning it is licensed not just for weight loss but also for reducing the risk of heart attack and stroke in high-risk patients.
Clinical trial results
The STEP-1 trial, the main evidence base for Wegovy's weight management licence, found average weight loss of 14.9% over 68 weeks at the 2.4mg maintenance dose, compared to 2.4% with placebo. Around one in three participants lost more than 20% of body weight.
The SELECT trial tested Wegovy specifically for cardiovascular outcomes in 17,604 adults with established cardiovascular disease and a BMI ≥ 27. Participants on semaglutide were 20% less likely to experience a major cardiovascular event (heart attack, stroke, or cardiovascular death) compared to placebo over approximately three years. NICE noted that benefits appeared early, before substantial weight loss had occurred, suggesting an effect beyond weight reduction alone.
New: 7.2mg dose approved January 2026. The MHRA approved a higher maintenance dose of 7.2mg in January 2026 — the first regulator globally to do so. In the STEP-UP trial this dose achieved average weight loss of 20.7%. Check availability above.
Doses and titration
Treatment starts at 0.25mg weekly for four weeks, then increases to 0.5mg, 1mg, 1.7mg and finally 2.4mg — each step held for four weeks. The standard maintenance dose is 2.4mg. For patients who need or tolerate it, the new 7.2mg dose is now available as a higher maintenance option following separate MHRA approval.
Who is it for?
Private prescription
BMI ≥ 30, or BMI ≥ 27 with a weight-related condition
Adults aged 18 and over
Not pregnant or planning pregnancy
No personal or family history of medullary thyroid cancer or MEN2
Who should not take Wegovy: people who are pregnant or planning to become pregnant, those breastfeeding, and anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Wegovy is not indicated for people with type 1 diabetes.
Oral contraceptive pill:NHS England advises that semaglutide may reduce the effectiveness of the contraceptive pill by slowing gastric absorption. Use an additional method of contraception for four weeks after starting treatment and for four weeks after each dose increase.
Side effects
Most side effects are gastrointestinal, most common at the start of treatment or after a dose increase, and typically settle as the body adjusts. The slow titration schedule is designed to minimise them.
Nausea
Very common, especially in the early weeks or after dose increases. Usually mild and temporary.
Diarrhoea / constipation
Common. Staying well hydrated and eating smaller meals helps.
Vomiting
Common at dose increases. Eating slowly and avoiding large meals reduces the risk.
Abdominal pain
Mild stomach discomfort is common, particularly early in treatment.
Injection site reactions
Mild redness or discomfort. Rotating injection sites reduces frequency.
Pancreatitis (rare)
Severe abdominal pain with or without vomiting — seek immediate medical help.
Hair loss is reported by some patients and is typically associated with rapid weight loss rather than the medication itself. Full side effect information is in the Wegovy patient information leaflet (EMC).
Frequently asked questions
Wegovy (semaglutide) acts on the GLP-1 receptor only. Mounjaro (tirzepatide) acts on both GLP-1 and GIP, which is thought to explain why Mounjaro produces greater average weight loss in clinical trials (~20% vs ~15–17%). However, Wegovy has a significant clinical advantage: it is the only GLP-1 medication with a NICE-approved cardiovascular indication, reducing the risk of heart attack and stroke by ~20% in high-risk patients. Wegovy is also generally cheaper at equivalent stages of treatment.
In April 2026, NICE recommended Wegovy for a new indication: reducing the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults who have established cardiovascular disease — meaning a prior heart attack, stroke, or peripheral arterial disease — and a BMI of at least 27. This is separate from the weight management indication and has no two-year time limit. Around 1.2 million people in England are estimated to be eligible. The evidence comes from the SELECT trial, which showed a 20% reduction in serious cardiovascular events compared to placebo.
The MHRA approved a 7.2mg dose of Wegovy in January 2026, making the UK the first country globally to approve this higher strength. In the STEP-UP clinical trial, the 7.2mg dose achieved average weight loss of 20.7% — close to the results seen with Mounjaro. It is intended for patients who have been established on 2.4mg and require or can tolerate a higher dose. Not all pharmacies stock this dose yet; use the tabs above to check current availability and prices.
Yes, via two routes. For weight management (NICE TA875): you need a BMI of 35 or above with at least one weight-related comorbidity, a referral to a specialist weight management service, and treatment is capped at 2 years. For cardiovascular risk reduction (new April 2026 guidance): you need established cardiovascular disease and a BMI of 27 or above — this route has no time limit and is expected to be available via GPs and cardiologists within months. Most patients seeking Wegovy for weight loss currently access it through private prescription due to NHS waiting times.
They contain the same active ingredient — semaglutide — but at different doses for different purposes. Wegovy is licensed for weight management in the UK at doses up to 2.4mg (and now 7.2mg). Ozempic is licensed for type 2 diabetes only, at a lower maximum dose of 1mg in the UK. Ozempic should not be used for weight loss — it is not licensed for that indication in the UK and should only be prescribed to people with type 2 diabetes.
Most patients notice reduced appetite within the first few weeks of starting Wegovy. Visible weight loss typically becomes apparent from around weeks 4–8. The full titration from 0.25mg to the 2.4mg maintenance dose takes approximately 16 weeks. Clinical trials measured results at 68 weeks (about 16 months).
Clinical evidence shows that most patients regain a significant portion of lost weight after stopping semaglutide, as the appetite-suppressing effects cease when the drug clears the body. This reflects the chronic nature of obesity rather than a drug failure. For patients using Wegovy for cardiovascular risk reduction, stopping treatment removes the cardiovascular protective effect. Stopping should always be discussed with a prescriber.
Two NHS routes: weight management (specialist services, max 2 yrs) and cardiovascular risk (BMI ≥ 27 with prior CVD — new April 2026, no time limit). Full NHS eligibility guide →